Clinical Trial

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-12-09; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2023-08-21
Trial Details
NCT Number NCT05655949
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Sirtex Medical, Dana-Farber Cancer Institute
Conditions Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Enrollment 30 participants
Start Date 2024-02-13
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-22